Interleukin-2 injection for small triple negative breast tumors
Part of Cancer, Skin clinical trials.
This trial tests whether injecting interleukin-2 directly into small breast tumors before surgery can help the immune system fight the cancer. It is for women with small triple negative breast cancer who are not receiving chemotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 80.
- You have been diagnosed with triple negative breast cancer (a type that lacks certain receptors).
- Your tumor is 2 cm or smaller and has not spread to lymph nodes (clinical T1N0).
- You are not scheduled to receive chemotherapy before surgery, either by choice or because you cannot tolerate it.
- You are able to come to the hospital for injections into the tumor and for study visits.
- You are not pregnant or breastfeeding, and you do not have certain heart, lung, or other health conditions that would make interleukin-2 unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.